Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Risperidone
Drug ID BADD_D01951
Description Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder.[L12885] It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).[L12885] Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively.[L1212,L1213] Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain.[L1213,A1115] Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors,[L1212,L1213,A1115] and carries lesser activity at several off-targets which may responsible for some of its undesirable effects.[L12885]
Indications and Usage Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder.[L12885] It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.[L12885] Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.[L12906] Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.[A177226]
Marketing Status approved; investigational
ATC Code N05AX08
DrugBank ID DB00734
KEGG ID D00426
MeSH ID D018967
PubChem ID 5073
TTD Drug ID D01AZG
NDC Product Code 12578-303; 57451-1185; 64567-0003; 65757-728; 65862-365; 12496-0090; 13668-035; 13668-039; 50458-306; 50458-325; 51759-410; 55700-897; 59746-050; 65841-670; 68071-2706; 68084-277; 69238-2108; 70518-1613; 70518-2969; 70518-3741; 71610-045; 71610-246; 0615-8197; 0615-8265; 0904-6360; 63552-180; 42291-913; 49884-315; 51759-850; 55154-4161; 59746-010; 63304-950; 63629-2283; 68084-271; 68382-154; 69238-2113; 70518-1151; 55111-869; 65267-895; 65757-727; 27241-004; 27241-005; 27241-006; 42291-908; 50458-335; 50458-355; 51759-305; 51759-520; 58118-0077; 59746-040; 63629-2284; 65841-642; 65841-668; 0054-0063; 68084-270; 70518-0364; 70518-3087; 70518-3760; 55154-3361; 55154-5899; 63187-264; 63187-642; 63304-643; 65862-167; 68084-273; 71335-0130; 0615-8196; 0904-6358; 71161-131; 27241-003; 49884-403; 50458-302; 50458-308; 51759-960; 63187-439; 68382-155; 70518-1502; 71205-520; 71335-0626; 0904-6361; 65757-725; 13668-037; 27808-002; 43063-908; 43547-344; 49884-311; 49884-401; 54838-563; 59746-030; 63304-951; 65841-641; 65841-667; 68084-272; 70518-1574; 70518-1771; 71610-259; 0615-8198; 72526-102; 72526-104; 63415-0037; 63552-179; 64220-119; 64552-4011; 42291-911; 43547-343; 49884-402; 50458-300; 50458-315; 50458-395; 51759-630; 53002-1596; 65841-640; 65841-666; 68084-274; 68382-114; 68382-115; 70518-1575; 71610-264; 53104-7555; 65015-619; 65757-726; 65841-122; 12496-0120; 42291-909; 43063-254; 43353-412; 43353-720; 43547-339; 49884-212; 50090-3340; 50458-309; 50458-350; 51759-740; 59746-020; 62135-929; 63304-949; 68382-156; 70518-1568; 70518-1763; 71335-0459; 71335-0740; 0615-8288; 72526-103; 52038-007; 65372-1105; 27241-002; 43547-340; 43547-341; 43547-342; 50090-3344; 50458-305; 50458-307; 50458-596; 63187-418; 65162-673; 65841-669; 69238-2110; 70518-2130; 70518-3104; 0904-6359; 0904-6362; 13668-036; 13668-038; 27241-001; 42291-910; 42291-912; 43353-432; 50090-3341; 50458-320; 50458-330; 63304-644; 65841-665; 68382-112; 68382-113; 68382-116; 68382-117; 69238-2109; 69238-2111; 69238-2112; 70518-0978; 72162-2037; 72526-101; 0904-6357; 40700-0031; 46602-0050; 65267-303; 71161-132; 13668-040
UNII L6UH7ZF8HC
Synonyms Risperidone | Risperdal Consta | Consta, Risperdal | Risperidal | R-64,766 | R 64,766 | R64,766 | R-64766 | R 64766 | R64766
Chemical Information
Molecular Formula C23H27FN4O2
CAS Registry Number 106266-06-2
SMILES CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Brain oedema17.07.02.003; 12.01.10.0100.001455%
Weight fluctuation14.03.02.0020.000412%Not Available
Autoimmune thyroiditis10.04.08.006; 05.02.04.0020.000121%Not Available
Osteopenia15.02.03.003; 14.04.04.0040.000630%Not Available
Emotional distress19.04.02.0080.099590%Not Available
Psychomotor skills impaired19.22.01.002; 17.02.10.0050.001091%Not Available
Sudden cardiac death08.04.01.008; 02.03.04.0160.000303%Not Available
General physical health deterioration08.01.03.0180.002728%Not Available
Homicidal ideation19.05.01.0080.000546%Not Available
Quadriparesis17.01.04.0120.000121%Not Available
Left ventricular dysfunction02.04.02.0110.000424%
Left ventricular hypertrophy02.04.02.0140.000121%Not Available
Muscle tightness15.05.03.0070.000655%Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Breast discomfort21.05.05.0070.000242%Not Available
Bradyphrenia19.10.03.002; 17.03.03.0040.000546%Not Available
Abulia19.01.02.009; 17.02.05.0400.000242%Not Available
Injection site cellulitis11.02.01.012; 08.02.03.037; 23.11.02.012; 12.07.03.037--Not Available
Subileus07.13.01.0040.000303%Not Available
Lupus-like syndrome15.06.02.004; 23.03.02.004; 10.04.03.0030.000424%Not Available
Electrocardiogram PR interval13.14.05.036--Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.012--
Deep vein thrombosis24.01.02.0030.005395%Not Available
Self-injurious ideation19.12.01.0070.000327%Not Available
Tonic clonic movements17.12.03.0060.000121%Not Available
Facial paresis17.04.03.0020.000364%
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Metabolic syndrome24.08.02.014; 14.06.02.007; 05.06.02.0070.002716%Not Available
Gastrointestinal hypomotility07.02.02.0050.000182%Not Available
Eyelid margin crusting23.03.03.029; 06.04.04.005--Not Available
The 27th Page    First    Pre   27 28 29 30 31    Next   Last    Total 37 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene